BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25247196)

  • 1. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
    Sengupta S; Thaci B; Crawford AC; Sampath P
    Biomed Res Int; 2014; 2014():952128. PubMed ID: 25247196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
    Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
    Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
    Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
    Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.
    Liang R; Wu C; Liu S; Zhao W
    Drug Deliv; 2022 Dec; 29(1):1620-1630. PubMed ID: 35612318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
    Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.
    Balyasnikova IV; Wainwright DA; Solomaha E; Lee G; Han Y; Thaci B; Lesniak MS
    J Biol Chem; 2012 Aug; 287(36):30215-27. PubMed ID: 22778273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
    Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
    Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
    Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
    PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
    Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
    Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors.
    Kim JW; Young JS; Solomaha E; Kanojia D; Lesniak MS; Balyasnikova IV
    Sci Rep; 2015 Dec; 5():18133. PubMed ID: 26656559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Bielamowicz K; Fousek K; Byrd TT; Samaha H; Mukherjee M; Aware N; Wu MF; Orange JS; Sumazin P; Man TK; Joseph SK; Hegde M; Ahmed N
    Neuro Oncol; 2018 Mar; 20(4):506-518. PubMed ID: 29016929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New perspectives in glioma immunotherapy.
    Daga A; Bottino C; Castriconi R; Gangemi R; Ferrini S
    Curr Pharm Des; 2011; 17(23):2439-67. PubMed ID: 21827420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model T muscle CARs can treat brain tumors.
    Johnson LA
    Clin Cancer Res; 2012 Nov; 18(21):5834-6. PubMed ID: 23019306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
    Khristov V; Nesterova D; Trifoi M; Clegg T; Daya A; Barrett T; Tufano E; Shenoy G; Pandya B; Beselia G; Smith N; Mrowczynski O; Zacharia B; Waite K; Lathia J; Barnholtz-Sloan J; Connor J
    J Neurooncol; 2022 Dec; 160(3):743-752. PubMed ID: 36436150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.